INTRODUCTION
There has been a burgeoning literature about pharmacotherapy and behavioral treatment of nightmare disorder in adults, but no systematic review has been available. The Standards of Practice Committee (SPC) of the American Academy of Sleep Medicine (AASM) commissioned a task force to assess the literature on the treatment of nightmare disorder. The Board of Directors authorized the task force to draft a Best Practice Guide based on review and grading of the literature and clinical consensus.
METHODS
The SPC of the AASM commissioned among its members 7 individuals to conduct this review and develop best practice principles. Work began in December 2007 to review and grade evidence in the peer-reviewed scientific literature regarding the treatment of nightmare disorder in adults. A search for articles on the medical treatment of nightmare disorder was conducted using the PubMed database, so that clinically relevant articles on the treatment of nightmare disorder could be collected and evaluated. Other databases such as PsychLit and Ovid were not searched, since it was felt that these databases would not include clinically relevant material. The PubMed search was conducted with no start date limit until February 2008, and subsequently updated in March 2009 to include the most current literature. The key words were: [(Nightmares OR nightmare OR nightmare disorder OR nightmare disorders OR recurrent nightmares) AND (treatment OR drug therapy OR therapy)] as well as [Post-traumatic stress disorder AND (nightmare disor-reviewed to determine if they met inclusion criteria. The articles had to have a minimum of 3 subjects to be included in the analysis. The articles had to address at least one of the "PICO" questions (acronym standing for Patient, Population or Problem, provided a specific Intervention or exposure, after which a defined Comparison is performed on specified Outcomes) that were decided upon ahead of the review process (see Table 1 ). Articles meeting these criteria in addition to those identified by pearling (i.e., checking the reference sections of search results for articles otherwise missed) provided 57 articles for review and grading.
Evidence was graded according to the Oxford Centre for Evidence-based Medicine Levels of Evidence ( Table 2) . 1 All evidence grading was performed by independent review of the article by 2 members of the task force. Areas of disagreement were addressed by the task force until resolved. Recommendations were formulated based on the strength of clinical data and consensus attained via a modified RAND/UCLA Appropriateness Method. 2 The nomenclature for the recommendations and levels of recommendation are listed in Table 3 . Recommendations were downgraded if there were significant risks involved in the treatment or upgraded if expert consensus determined it was warranted. This Best Practice Guide with recommendations was then reviewed by external content experts in the area of nightmare disorder.
The Board of Directors of the AASM approved these recommendations. All members of the AASM SPC and Board of Directors completed detailed conflict-of-interest statements and were found to have no conflicts of interest with regard to this subject.
The Best Practice Guide endorses treatments based on review of the literature and with agreement by a consensus of the task force. These guidelines should not, however, be considered inclusive of all proper methods of care or exclusive of other methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding propriety of any specific care must be made by the physician, in light of the individual circumstances presented by the patient, available diagnostic tools, accessible treatment options, and resources.
The AASM expects these recommendations to have an impact on professional behavior, patient outcomes, and, possibly, health care costs. These assessments reflect the state of knowledge at the time of publication and will be reviewed, updated, and revised as new information becomes available.
der OR recurrent nightmares OR nightmares) AND treatment]. A second search using the keyword combination "anxiety dreams" with no limits was also conducted in February 2010. "Post-traumatic stress disorder," alone, was not a search term. Although the majority of studies of both pharmacologic and nonpharmacologic treatments of posttraumatic stress disorder (PTSD) assess improvement of global manifestations, very few of these studies have isolated nightmares for evaluation of response to intervention and may not have included "nightmares" as a keyword. The evidence basis for this Best Practice Guide includes only those PTSD studies in which improvement in nightmares could be specifically identified as an evaluable outcome measure.
Each search was run separately and findings were merged. When the search was limited to articles published in English and regarding human adults (age 19 years and older), a total of 1428 articles were identified. Abstracts from these articles were : CAPS-DX (formerly CAPS-1), a diagnostic version to assess PTSD symptom severity over the past month or for the worst month since the trauma; CAPS-SX (formerly CAPS-2), a symptom status version to measure PTSD symptom severity over the past week intended for repeated assessments over relatively brief intervals; and a combined version called CAPS. Other psychometric scales have been used including the Symptom Checklist-90 (SCL-90), 11 a 90-question instrument that evaluates a broad range of psychological problems and can be used for measuring patient progress or treatment outcomes, and the Symptom Questionnaire (SQ), 12 a yes/no questionnaire with brief and simple items on state scales of depression, anxiety, anger-hostility, and somatic symptoms.
Overnight polysomnography (PSG) is not routinely used to assess nightmare disorder but may be appropriately performed to exclude other parasomnias or sleep-disordered breathing. PSGs may underestimate the incidence and frequency of PTSDassociated nightmares and may also influence the contents of the dreams. 13 Patients with both idiopathic and PTSD-associated nightmares have increased phasic R sleep activity, decreased total sleep time, increased number and duration of nocturnal awakenings, decreased slow wave sleep, and increased periodic leg movements during both R and NREM (N) sleep. 14 PTSD-associated nightmares, though commonly reported in R sleep, can occur earlier in the night, during sleep onset, and in N sleep. 15 Patients with PTSD-associated nightmares compared to those with idiopathic nightmares have decreased sleep efficiency due to higher nocturnal awakenings, 16 and a higher incidence of other parasomnias and sleep-related breathing disorders.
Consequences of nightmare disorder
Nightmare disorder is common, affecting about 4% of the adult population 3 with a higher proportion affecting children and adolescents. The presence of nightmare disorder can impair quality of life, resulting in sleep avoidance and sleep deprivation, with a consequent increase in the intensity of the nightmares. Nightmare disorder can also predispose to insomnia, daytime sleepiness, and fatigue. [17] [18] [19] It may also cause or exacerbate underlying psychiatric distress and illness. Nightmare disorder can be associated with waking psychological dysfunction, with the frequency of nightmares being inversely correlated with measures of well-being and measures of nightmare distress being associated with psychopathology such as depression and anxiety. 20 Patients who have their nightmares successfully treated appear to have better sleep quality, feel more rested on awakening, and report less daytime fatigue and sleepiness, and improvement in their symptoms of insomnia. [17] [18] [19] 
TREATMENT FOR NIGHTMARE DISORDER

Types of nightmares
Nightmares may be idiopathic (without clinical signs of psychopathology) or associated with other disorders including PTSD, substance abuse, stress and anxiety, and borderline personality, and other psychiatric illnesses such as schizophreniaspectrum disorders. Eighty percent of PTSD patients report nightmares ("PTSD-associated nightmares"). 4 PTSD is a condition manifesting symptoms classified in three clusters: (1) intrusive/re-experiencing, (2) avoidant/numbing, and (3) hyperarousal. Nightmares are generally considered to be a component of the intrusive/re-experiencing symptom cluster. It is not clear that nightmares unrelated to PTSD coexist with features of the other PTSD symptom clusters, specifically hyperarousal. 5 Nevertheless, among nightmares, the PTSD-associated nightmare is the most studied. Presence of nightmares following a traumatic experience predicts delayed onset of PTSD. Even when PTSD resolves, PTSD-associated nightmares can persist throughout life. 3 Nightmares can also be induced following exposure to drugs that affect the neurotransmitters norepinephrine, serotonin, and dopamine. 6 Withdrawal of R-suppressing agents, and drugs affecting GABA and acetylcholine, can also be associated with nightmares. 3 Whether nightmares induced by drugs have long term sequelae (even after removing the offending agent) is not known. It is not clear if these different types of nightmares have a common underlying pathophysiology.
Assessment
Self-reported retrospective questionnaires and prospective logs are the most commonly used methods to assess nightmare characteristics. Though retrospective questionnaires could lead to underestimation of nightmare frequency due to recall bias, 7 prospective logs may overestimate the frequency of nightmares by increasing dream recall by an increased focus on dreams. 8 The advantage of using self-reported questionnaires and logs are that they can distinguish nightmare frequency from distress. The gold standard diagnostic interview for PTSD is ClinicianAdministered PTSD Scale (CAPS). 9 This scale, which was developed by the National Center for PTSD, is a structured interview that assesses the frequency and intensity of 17 symp-be moderately to strongly beneficial in all the studies. Ninetyeight patients were studied. The 3 Level 1 studies evaluated 10 Vietnam combat veterans (mean age 53 years), 29 34 military veterans (mean age 56 years), 28 and 13 civilian trauma victims (mean age 49 ± 10 years, 11/13 women) 27 in placebo-controlled trials; all found a statistically significant reduction in traumarelated nightmares versus placebo as measured by Item No. 2 "recurrent distressing dreams" on CAPS (initial rating 4.8 to 6.9 in the Level 1 studies; final rating after prazosin treatment was 3.2 to 3.6). The treatment length ranged from 3 to 9 weeks. All patients maintained their ongoing concurrent psychotherapy and psychotropic medications during the trials. Treatment was generally started at 1 mg at bedtime and increased by 1 to 2 mg every few days until an effective dose was reached. The average dose was approximately 3 mg, although 1 mg to over 10 mg were used and found to be effective, with higher doses used in 2 of the Level 1 studies treating PTSD-associated nightmares in military veterans (mean of 9.5 mg/day 29 and 13.3 mg/ day 28 ). In all of the studies, prazosin appeared to be generally well tolerated; nevertheless, the clinician should monitor the patient for orthostatic hypotension.
Clonidine may be considered for treatment of PTSDassociated nightmares. Level C
Clonidine is an α 2 -adrenergic receptor agonist that suppresses sympathetic nervous system outflow throughout the brain. It is widely used to treat opioid withdrawal, in which context it blocks an elevated startle reaction. Clonidine shares the therapeutic rationale as well as the potential for postural hypotension of prazosin but has not been investigated with the same rigor. It has been reported that low-dose clonidine increases R sleep and decreases N sleep, whereas medium-dose clonidine decreases R sleep and increases N2 sleep. 34 There were 2 Level 4 case series demonstrating efficacy of 0.2 to 0.6 mg clonidine (in divided doses) to reduce the number of nightmares in 11/13 Cambodian refugees (no statistical analysis done). 35, 36 Followup ranged from 2 weeks to 3 months with one report of a fall in blood pressure with increasing dose. These were from a single site, and 9 were also treated with imipramine. Boehnlein and Kinzie 24 report that "clonidine has been a mainstay of PTSD treatment for severely traumatized refugees for over 20 years," yet no randomized placebo-controlled trials of clonidine for the treatment of nightmares or other aspects of PTSD have been reported. Despite the long history of use and the pharmacologic similarity to prazosin, the paucity of hard data relegates this medication to a lower level recommendation.
4.1.3
The following medications may be considered for treatment of PTSD-associated nightmares, but the data are low grade and sparse: trazodone, atypical antipsychotic medications, topiramate, low dose cortisol, fluvoxamine, triazolam and nitrazepam, phenelzine, gabapentin, cyproheptadine, and tricyclic antidepressants. Nefazodone is not recommended as first line therapy for nightmare disorder because of the increased risk of hepatotoxicity. Level C
Trazodone
A Level 4 survey 37 of 74 patients who were given trazodone found that it was effective in decreasing the frequency of nightingly, there are no large-scale, well-controlled trials comparing pharmacologic with non-pharmacologic therapies. 
The following are medication treatment options for nightmare disorder
A variety of medications have been studied for possible benefit in patients with nightmares. The studies of most medications assess efficacy only in the treatment of PTSD-associated nightmares. It is unknown if treatments that demonstrate efficacy for PTSD-associated nightmares are also effective for idiopathic or drug-related nightmares, or if these therapies would work for patients who have bad dreams that do not fulfill ICSD-2 criteria for nightmare disorder, such as those that occur in the first half of the night or that are not associated with an awakening. Even if the focus is limited to PTSD-associated nightmares, there is an insufficient number of controlled trials to formulate rigorous evidence-based guidelines on nightmare disorder, 22 although an evidence-based systematic review of pharmacotherapy for PTSD, not specifically related to improvement in nightmares, has been published. 23 Many patients with PTSD are on multiple psychotropic medications, making the assessment of efficacy of monotherapy of any particular medication difficult. A summary of the volume and grade of literature is in Appendix Table 1 and discussed in detail below.
Prazosin is recommended for treatment of PTSDassociated nightmares. Level A
The rationale for the use of pharmacologic reduction of CNS adrenergic activity in the treatment of PTSD has recently been reviewed by Boehnlein and Kinzie. 24 Norepinephrine appears to play an important role in the pathophysiology of PTSDrelated nightmares, arousal, selective attention, and vigilance. Norepinephrine levels in the cerebrospinal fluid and urine are elevated in patients with PTSD. CSF norepinephrine concentration appears to correlate with the severity of PTSD symptoms. It has been proposed that the consistently elevated CNS noradrenergic activity may contribute to disruption of normal R sleep and that agents that reduce this activity could be effective for treatment of some manifestations of PTSD, particularly arousal symptoms such as nightmares and startle reactions. 24 Propranolol, a non-selective β-adrenergic blocker, has been investigated for treatment and perhaps prevention of PTSD. 25 Paradoxically, β-blockers are often associated with sleep disorders including nightmares and insomnia. 26 The literature review found no studies related to the use of propranolol or other beta-blockers for treatment of nightmares, even in patients with PTSD.
Prazosin is an α 1 -adrenergic receptor antagonist introduced as an antihypertensive agent. It reduces CNS sympathetic outflow throughout the brain. Several CNS phenomena implicated in the pathogenesis of PTSD are regulated by α 1 -adrenergic receptors including a number of sleep/nightmare phenomena, and cognitive disruption. 24 In a placebo-controlled study, the effects of prazosin on sleep included increased total sleep time, increased REM sleep time, and increased mean R period duration without alteration of sleep-onset latency. 27 The data supporting efficacy of prazosin in the treatment of PTSD-associated nightmares consist of 3 Level 1 placebocontrolled studies, [27] [28] [29] all of which are from the same group of investigators, and 4 Level 4 studies. [30] [31] [32] [33] Prazosin was found to
Practice Guide for the Treatment of Nightmare Disorder portedly reduced nightmares in 79% of patients, with full suppression in 50%. The final dosage for 91% of full responders was 100 mg/day or less, but the range was 12.5 to 500 mg/day. Follow-up ranged from 1 to 119 weeks. Nine patients discontinued treatment due to side effects, which included urticaria, eating cessation, acute narrow-angle glaucoma, severe headaches, overstimulation/panic, emergent suicidal ideation, and memory concerns.
Low-dose corTisoL
Low-dose cortisol (10 mg/day, either in the morning or half at noon and half in the evening) was found to have mediumto-high benefit with low side effects in 3 civilians with PTSD in a Level 4 study for 1 month. 44 There was a significant reduction in the frequency of nightmares but not intensity in 2 subjects; there were no data on nightmare effect for the third subject. One of the patients was also on mianserin and chlorprothixene. There were no reported side effects and no longterm follow-up.
FLuvoxamine
Two Level 4 case series 45, 46 showed moderate-to-high efficacy in 42 patients with up to 300 mg fluvoxamine. One study 46 of 21 Vietnam veterans reported a statistically significant fall in the Impact of Event Scale-Revised (IES-R) level of "dreams about combat trauma" but a non-significant fall in the rating of "bad dreams" from the Stress Response Rating Scale at 10 weeks. No side effects were noted in the study. The patients were on no other psychoactive medications. The second study 45 of 24 Dutch WWII Resistance veterans reported a qualitative decrease in nightmares in 12 subjects. No further details were given. Of note, 12 subjects dropped out of the trial, 9 due to gastrointestinal problems and worsening of sleep, and 3 for physical complaints not related to fluvoxamine. Followup ranged from 4 to 12 weeks. Some of the patients were on benzodiazepines.
TriazoLam and niTrazepam
In a 3-day Level 2 cross-over study 47 comparing the hypnotic efficacy of triazolam versus nitrazepam in 40 patients with "disturbed sleep," 0.5 mg triazolam was found to be superior to 5 mg nitrazepam in terms of objective measures of sleep duration and quality. However, both drugs were equally effective at reducing the number of subjects who noted unpleasant dreams, from 23 prior to medication administration to 1 subject for nitrazepam and 2 subjects for triazolam. Each drug was given for just one night and the measure of nightmare frequency was limited. There was no difference in side effects, which were considered minor and consisted of difficulty concentrating in the morning and morning sedation.
pheneLzine
Two Level 4 studies 48,49 studied phenelzine as a single medication in a total of 26 military veterans. The dosage in these studies ranged from 30 to 90 mg. One study 48 with 5 subjects found that phenelzine eliminated nightmares entirely within 1 month with long-term follow-up up to 18 months later. Three of the 5 subjects were nightmare-free without medication. The other study 49 demonstrated a fall in an average "traumatic mares but also had significant side effects. Olanzapine is an atypical neuroleptic which has been shown to be useful in the treatment of schizophrenia and bipolar mania. It was used in a small uncontrolled case series 38 (Level 4 evidence) of 5 patients with combat-related PTSD resistant to treatment with SSRIs and benzodiazepines because of reports that it improved sleep. The authors reported rapid improvement after 10-20 mg olanzapine was added to the current psychotropic treatment regimen. There was no quantification of medication effect and no long-term follow-up. No adverse events were seen. 38 Risperidone is an atypical antipsychotic medication that demonstrates significant α 1 -noradrenergic antagonism. 39 Two Level 4 case series 40, 41 showed moderate to high efficacy of risperidone in treating patients with PTSD-related nightmares. The 6-week results of an open-label, flexible dosage (1 to 3 mg/ day) trial 40 of 17 Vietnam combat veterans showed a statistically significant fall in the CAPS score of recurrent distressing dreams (p = 0.04) with a reduction in the proportion of diaries documenting trauma dreams (38% to 19%, p = 0.04). Many of these patients were taking others medications as well (antidepressants, mood stabilizers, and anxiolytics). A retrospective study 41 of 10 adult burn patients on pain medications reported that all subjects experienced improvement in nightmares (no quantitative analysis done), as well as other distressing acute stress symptoms, 1-2 days after starting risperidone (0.5 to 2 mg; average 1 mg). Neither study reported side effects, and there was no long-term follow-up.
There is a Level 4 case series 42 on the effect of aripiprazole with CBT or with sertraline in 5 patients suffering from combat-related PTSD. Aripiprazole, 15 to 30 mg at bedtime, resulted in significant improvement but not total resolution of sleep disturbances such as nightmares in 4/5 cases. The patient who did not respond stopped the medication because of agitation and inability to sleep. Duration of follow-up was not specified.
TopiramaTe
A Level 4 case series 43 studied the efficacy of topiramate in 35 civilians who suffered from PTSD primarily due to physical assault or unwanted sexual experience. Dosage titration began at 12.5 to 25 mg daily and was increased in 25 to 50 mg increments every 3 to 4 days until a therapeutic response was achieved or the drug was no longer tolerated. Topiramate re-no worsening of nightmares and no reported side effects. Unfortunately, they were all on different regimens, including imipramine as monotherapy (75 mg-125 mg; 3 subjects), imipramine (150 mg) with phenelzine alone or phenelzine and doxepin and amitriptyline (2 subjects), amitriptyline (100 mg) with doxepin (1 subject), and doxepin alone (50-100 mg, 4 subjects). The 2 subjects who did not have any improvement in nightmares were either on doxepin 100 mg or imipramine (150 mg) with doxepin (150 mg), phenelzine (30 mg bid), and amitriptyline (100 mg). Although follow-up occurred at 1 year, the paper did not detail the length of treatment with each medication. In addition to medication, the patients also had monthly clinic visits to discuss ways to handle stress.
neFazodone
There are 3 Level 4 studies that evaluated nefazodone as monotherapy in a total of 39 patients. An open-label 12-week clinical and sleep EEG study of 12 male veterans treated with nefazodone (mean dosage 441 mg) demonstrated significantly fewer nightmares (30% fewer at 12 weeks) and sleep problems. There were no changes in polysomnographic variables compared to baseline. 56 An additional study of 10 Vietnam-era veterans (dosage 500-600 mg/day) reported improvement in nightmares (as measured by a decrease in the IES-R nightmare assessment from 3.5 to 2.1, p = 0.003) in response to nefazodone. 57 A third uncontrolled study of 17 civilians with PTSD with a mean nefazodone dose of 386 ± 192 mg/day reported a 58.3% response rate for nightmares on the Structured Interview for PTSD (SIP) after 2 weeks of treatment and a 50% response rate at week 12. 58 This drug, now only available in generic form, must be used with caution and careful monitoring, as cases of hepatic failure have been associated with nefazodone. 59 The following side effects were noted in the studies: bitter taste, increased appetite, drowsiness, headache, dry mouth, dizziness, and hypersomnia.
Venlafaxine is not suggested for treatment of PTSDassociated nightmares. Level B
This assessment is based on 1 Level 1 study 60 of venlafaxine ER (37.5 to 300 mg/d) with 340 subjects treated for PTSD (combination of combat-related and non-combat related). This study was a pooled analysis of 2 randomized, double-blind, placebo-controlled trials assessing response (via CAPS-SX 17 ) at 12 weeks of therapy. The study showed no significant difference between the effects of placebo and venlafaxine ER in the CAPS-SX 17 item Distressing Dreams. No side effects were noted in the study, and there was no long-term follow-up. Although venlafaxine did not result in a greater improvement in nightmares than did placebo, it resulted in statistically significant improvement in 13 other PTSD symptoms when compared with placebo.
No recommendation is made regarding clonazepam because of sparse data.
This assessment is based on only 1 Level 2 study 61 of 6 veterans with PTSD and may be revised if more data become available. The study was a randomized, single-blind, placebo-controlled, crossover clinical trial which found that clonazepam was largely ineffective for treatment of sleep disdream" severity scale in 21 veterans from just above moderate (2.2/4) to just below moderate (1.8/4), a change that reflected an improvement of 18%, but just missed the level of statistical significance (p = 0.05). Six patients stopped treatment within 8 weeks because of a lack of improvement. Treatment was ultimately discontinued in the remaining subjects because the initial improvement was minor or short-lived or reached a plateau felt to be sufficiently unsatisfactory to justify a change to an alternate medication. Reported side effects included dizziness, drowsiness, and malaise. Although not specifically stated, the ability of phenelzine to reduce R sleep was cited. As an MAOI, phenelzine can cause a hypertensive crisis if taken with sympathomimetic medications or with high tyramine-containing foods. 
GabapenTin
There is a Level 4 study 51 of 30 veterans with PTSD that used adjunctive gabapentin at 300-3600 mg/day, most of whom were on antidepressants with some on antipsychotics and anxiolytics. The results showed a medium to high effect, with 77% of patients showing a moderate or greater improvement in insomnia, and most of those subjects noting a decrease in the frequency and/or intensity of nightmares over a follow-up period of 1 to 36 months (this response was not quantified in the paper). The mean dosage for patients with moderate or marked clinical improvement was 1344 ± 701 mg, and for those with mild or no improvement it was 685 ± 227 mg. Sedation and mild dizziness were the most commonly reported side effects.
cyprohepTadine
The evidence for cyproheptadine, which has serotonin antagonism properties, consists of 3 Level 4 papers with conflicting data. [52] [53] [54] A small case series 52 of 4 veterans with combat-related PTSD, who were said to be representative of "about 80" patients treated with effective doses ranging from 16-24 mg, reported that cyproheptadine eliminated nightmares in 3 patients on doses ranging from 2-6 mg nightly. When effective, it generally took effect within a few days. The proposed mechanism of effect was through increasing serotonin levels by blocking feedback inhibition. Long-term follow-up was not reported. A retrospective review 54 of psychiatric records of patients who received cyproheptadine as treatment for nightmares provided incomplete information. Only 9 patients whose responses varied from "complete remission" to decreased intensity and frequency were described in detail, and the total number of records reviewed was not reported. Four of 16 patients studied at a VA PTSD treatment center reported cyproheptadine to be effective but there was no change in report of nightmare presence and intensity over a one-month period at a dose of 4-8 mg in any of the 16 subjects. All but 2 of the 16 patients were taking a wide variety of other psychotropic medications. Side effects included drowsiness, irritability, hallucinations, nausea, headache, and worsening of nightmares. This recommendation is based on 1 Level 1, 67 1 Level 2, 68 1 Level 3, 69 and 7 Level 4 studies. 65, [70] [71] [72] [73] [74] [75] Although the Level 1, Level 2, and Level 3 studies are from a single site, the data are sufficiently compelling to merit a Level A recommendation. The Level 1 study 67 demonstrated that IRT is a brief, effective, well-tolerated treatment for chronic nightmares associated with PTSD. This RCT of 168 women with moderateto-severe PTSD symptoms demonstrated that IRT significantly improved disturbing dreams, sleep quality, and posttraumatic stress symptoms (60% reduction) and the effect was maintained at 3-and 6-month follow-up evaluations compared to control group. However, there was a high drop-out rate (32%) and the control group was a wait-list control [see footnote on page 398] and blinding for treatment was not possible.
A Level 2 study 68 demonstrated sustained reduction of nightmare frequency at 30 months in 2 groups of 10 patients each treated for chronic nightmares with CBT. The initial 3-month data were reported in an earlier Level 2 study 76 but were not considered separately as this longer-term report superseded the earlier reference. As part of CBT, 1 group learned IRT and the other group recorded the nightmares in a diary for 1 month. At 3-month follow-up the IRT group had a 72% reduction (p < 0.006) in nightmare frequency (7.2/month to 2.0/month) compared to a 42% reduction (p < 0.02) in frequency (9.4/month to 5.0/month) noted in the recording-only group. Interestingly the study showed that the IRT group also had substantial decrease in anxiety, somatization, hostility, and total distress scores on the SCL-90 and SQ when compared with the recording-only group (no p-value given). The subsequent addition of imagery rehearsal and rescripting to the first group that used only nightmare recording did not produce further decrease in symptoms at 30-month follow-up. The initial effects of these 2 individual techniques appeared to be the most potent in reducing nightmares.
In a Level 3 study 69 of 58 subjects with chronic nightmares, IRT demonstrated a clinically meaningful and significant decrease in nightmare frequency with long-term follow-up. At 18 months, 68% of the remaining 53 subjects no longer met criteria for nightmare disorder. This study is a follow-up from a prior Level 2 study 77 of 58 subjects with nightmare disorder who were not screened for psychiatric illness and likely represented both idiopathic and PTSD-associated nightmare disorder (personal communication from the author).
Additionally there were 7 other Level 4 studies, 65, [70] [71] [72] [73] [74] [75] comprising 187 subjects, that indicated strong benefits for IRT in the management of nightmares in patients with PTSD-associated and idiopathic nightmares. These were mainly case series or studies with few subjects and with either no control group or no blinding.
IRT appears to be effective in the management of nightmares exhibited in patients with PTSD as well as idiopathic nightmares. This was generally a well-tolerated treatment although there was 1 report 72 of a subject who developed paradoxical hyperarousal with an increase in nightmare frequency (although this could also represent the natural progression of the disorder). This may indicate the potential for this type of treatment to induce an exacerbation of PTSD symptoms during the therapeutic process. It is important to mention that several of the higher-level data are from a single-site or contributions associated with a particular expert in the field. Additional high level turbances associated with combat-related posttraumatic stress disorder. Although 1 to 2 mg of clonazepam at bedtime improved problems with sleep initiation and maintenance, the differences were not statistically significant and there was no improvement in nightmare intensity or frequency. Side effects were indiscernible from placebo, and there was no long-term follow-up.
The following are non-pharmacological treatment options for nightmare disorder
The etiology of nightmares is suggested to be multifactorial and may be influenced by psychological factors to a great extent. There is an immense literature demonstrating efficacy of psychotherapeutic interventions for PTSD, including trauma-focused Cognitive Behavioral Therapy (CBT). Traumafocused CBT, particularly IRT, has been shown to be effective treatment for sleep-related issues in PTSD as summarized in a systematic review 62 and 2 meta-analyses 63, 64 that included 36 RCTs related to disturbed sleep in PTSD patients. These studies focused on general sleep characteristics in PTSD and not specifically on nightmares. The discussion that follows addresses the efficacy of those treatments for nightmares. Although some treatments were only studied on patients with PTSD, it is possible that these treatment modalities would also be effective in patients with idiopathic nightmares or disturbing dreams that do not fulfill ICSD-2 criteria, as illustrated by the efficacy of IRT in a diverse patient population. Appendix Box 1 summarizes the non-pharmacological therapies available to the practitioner for patients suffering from nightmare disorder.
Cognitive Behavioral Therapy (CBT)
CBT is psychotherapeutic approach that focuses on distorted/dysfunctional thoughts, emotions, and behavior through a goal-oriented, structured and time limited procedure. CBT is often used as a broad term for a number of psychotherapeutic and behavioral techniques tailored to uncover, alter, and correct distortions of cognition and behavior in an individual. Some of the early interventions used basic CBT principles 65, 66 effectively to manage nightmares until more effective and specialized CBT 67 This technique is practiced for 10-20 minutes per day while awake. 4 
Self-exposure Therapy is a variant of CBT that utilizes a technique of "graded exposure." The patient is instructed to make a hierarchical list of anxiety-provoking events/dreams. The patient is then instructed to move through the situations on the list at his or her own rate, starting with lowest anxiety situation until the fear/anxiety has decreased. The exposure is done on a daily basis with documentation in a journal of his or her experiences.
This recommendation is based on 1 Level 2 and 1 Level 3 study of patients with idiopathic or PTSD related nightmares. The Level 2 RCT 81 involved 206 subjects randomized to 4 weeks of (a) self-exposure treatment at home (n = 83), (b) self-relaxation treatment at home (n = 61), and (c) a wait-list control group (n = 62), all instruction coming from a treatment manual received in the mail. Self-exposure therapy (p < 0.0005) was better than self-relaxation therapy or wait-list control for reducing nightmare frequency. The limitations of the study included a high drop-out rate (17%) and the fact that the nightmare intensity was not greatly reduced after 4 weeks of self-exposure, which may indicate the need for longer treatment duration. In a Level 3 open randomized study 82 involving 20 subjects with recurrent nightmares, 10 each were randomized to a correspondence-based self-exposure therapy trial and a control group. At the 4-week follow-up, the self-exposure group had significant improvements in nightmare frequency and intensity (p < 0.001), and the benefit was maintained at the 4-year follow-up. This small study had no drop-outs and the subjects served as their own controls. This recommendation is based on 1 Level 1, 1 Level 2, and 1 Level 4 study. The Level 1 study 83 compared Progressive Deep Muscle Relaxation (PDMR) (11 subjects) with systemic desensitization (10 subjects) and wait-listed controls (11 subjects). Although both intervention groups showed similar decrease in frequency of nightmares, at 25-week follow-up the desensitization group (p < 0.026) showed significantly greater reduction in nightmare intensity compared to the relaxation group (see PDMR section for details). A Level 2 8-week randomized control study 84 randomly assigned 29 subjects to a Systemic Desensitization treatment group (10 subjects), a continuous self-recording group (9 subjects), and a nightmare-related discussion placebo treatment group (10 subjects). The short-term Systemic Desensitization treatment was found to produce favorable changes in frequency (p < 0.01) and rated intensity of the nightmares (p < 0.01). However, follow-up nightmare information was available for only 65% of the subjects.
The Level 4 study 73 involved 36 subjects with chronic nightmares, of whom 14 received 1 single treatment instruction of desensitization with progressive muscle relaxation and 14 with studies from different sites demonstrating the effectiveness of treatment are limited. (5 subjects) . The Level 3 study demonstrated that at 12-week follow-up, 2 hours of individual LDT counseling (p = 0.0002) was more effective than 2 hours of group LDT (p = 0.02) instruction although both showed a statistically significant fall in the frequency of nightmares when compared with baseline. The wait-list control group (p = 0.30) did not demonstrate a statistically significant reduction. A Level 4 case series of 5 patients, with either idiopathic or PTSD nightmares, showed alleviation of recurrent nightmares at 1 year when lucid dreaming was added to the subjects who were initially trained in progressive muscle relaxation and guided imagery.
Low grade evidence suggests LDT may be helpful. However, it may have only limited applicability in terms of availability and incorporation of treatment. This assessment is based on 1 small Level 4 study. 80 ERRT was found to decrease the frequency and severity of traumarelated nightmares in 4 subjects at 3-and 6-month follow-up evaluations. 90 of 83 veterans with PTSD (including nightmares) compared EMDR with Relaxation training and Biofeedback at initial evaluation, hospital admission at 2 months or later, and 90 days after admission. This was an in-house program evaluation study (conducted at a VA-hospital-based inpatient PTSD program) rather than an experiment and was based on patient self-report. The EMDR subjects did better than controls and the other 2 treatment groups in all variables including nightmares (p < 0.01). The second cohort study 89 reported on 7 subjects who had nightmares and PTSD symptoms for at least 3 months after being assaulted or kidnapped. They were treated with 5 EMDR sessions. EMDR improved PTSD symptoms and quality of sleep. This study did not specifically address the quality and frequency of nightmares in these patients, but addressed recurrent nightmares as part of sleep quality which showed improvement (p = 0.003).
The Testimony method may be considered for treatment of PTSD-associated nightmares. Level C The Testimony method is a brief variant of a trauma exposure technique. Trauma survivors are invited to tell the story of their traumatic experiences and document them in a written format with the help of the therapist.
In a Level 3 case-control trial 91 in a community setting, 206 Mozambican civil war survivors were sorted into a case and a non-case group. The case group of 137 subjects was randomized to an intervention group and a control group. One 60-minute session of Testimony intervention was performed with each subject, although 7 cases required a second session. The nightmare impact (NITE) scores indicated significant reduction in anxiety dreams (p < 0.01) at post-intervention and 11-month follow-up. Although this study was designed as a case-control study, the local circumstances interfered with the design, especially with controlling the intervention in a small rural community. This assessment is based on a single Level 4 case series 92 of 3 veterans with PTSD and recurrent nightmares who responded well to individual psychotherapy. The therapeutic principle focused on understanding of the individual's war experiences and how they were represented in each individual's postwar life. The literature describes high-level effectiveness of this treatment modality in case reports and descriptive treatment protocols. RCTs and comparative studies are unavailable.
No recommendation is made regarding Individual
rehearsal of changed nightmares. Eight were excluded after intake. All subjects were contacted via telephone at 4 months and 7 months. Both the treatment groups showed a decrease in frequency of nightmares (p < 0.0001).
Although the studies are multicenter and well-designed, demonstrating statistical significance, more data on larger groups of subjects with lower drop-out rates would be helpful to fully understand the usefulness of this technique. This recommendation is based on 1 Level 1 study 83 of 32 females self-referred with complaints of nightmares. They were randomly assigned to PDMR training, systemic desensitization, and wait-list controls. Both treatments reduced nightmare frequency by 80% in 20/21 subjects (p = 0.001 compared with wait-listed controls), and 12 of these subjects had total elimination of symptoms. The treatment groups showed greater decrease in nightmare frequency compared to wait-listed controls (p < 0.001) at week 15. After week 25, although the effect on frequency of nightmares was favorable and consistent, the desensitization group had a more favorable effect on intensity (p < 0.026) of the nightmares, especially favoring the earlier-treated group (p < 0.046) over the later-treated wait-listed controls indicating improved benefit with longer duration of treatment.
Progressive Deep
The data for PDMR based on this 1 small study is statistically compelling. However, further research is warranted to validate these findings. This recommendation is based on 2 Level 4 studies. In a small case series 85 involving 10 patients with nightmares treated with hypnosis, 71% had improvement or were symptom-free at 18 months and 67% at 5-year follow-up. Another Level 4 case series 86 involving 3 subjects showed that brief hypnotic therapy of 1 to 5 sessions were found to be beneficial for repetitive nightmares. 
Hypnosis
Eye Movement Desensitization and
AREAS FOR FUTURE RESEARCH
There is a wealth of data about pharmacological and behavioral interventions for the treatment of nightmare disorder, yet a great majority of the research focuses on management of individual patients and case reports. Thus, there is paucity of research with randomized controlled trials and Level 1 studies. In addition, consistency in nightmare metrics would improve the ability to compare results among trials. There is also a need for investigations to determine if different approaches are necessary for idiopathic versus PTSD-associated nightmares. Emphasis should be placed on trials directly comparing various pharmacotherapy and behavioral techniques, combination treatments with medication and psychotherapy, and duplication and verification of results on a broader scale involving multicenter or registry approaches.
FOOTNOTE FROM PAGE 395
This refers to a group of people in the waiting list scheduled to get the intervention in the future, who serve as the control group while the active group receives the intervention. This method is usually used in psychotherapeutic outcome trials. Usually everyone receives the intervention by the end of the study.
